Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Tao Zhang^#¹, Rong Qu^#¹, Shingpan Chan^#², Mengzhen Lai^{1

3}, Linjiang Tong¹, Fang Feng¹, Hongyu Chen⁴, Tingting Song⁴, Peiran Song¹, Gang Bai^{1

5

6}, Yingqiang Liu^{1

3}, Yanan Wang¹, Yan Li¹, Yi Su¹, Yanyan Shen¹, Yiming Sun¹, Yi Chen¹, Meiyu Geng¹, Ke Ding⁷, Jian Ding⁸, Hua Xie⁹

Affiliations

¹ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.
² International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China.
³ School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China.
⁴ Jiangsu Aosaikang Pharmaceutical Co.Ltd (ASK pharm), 699 Kejian Road, Nanjing, 211112, China.
⁵ University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing, 100049, China.
⁶ School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai, 201210, China.
⁷ International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China. dingke@jnu.edu.cn.
⁸ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. jding@simm.ac.cn.
⁹ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. hxie@simm.ac.cn.

^# Contributed equally.

PMID: 34404402
PMCID: PMC8369743
DOI: 10.1186/s12943-021-01391-x

Published Erratum

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Tao Zhang et al. Mol Cancer. 2021.

. 2021 Aug 17;20(1):102.

doi: 10.1186/s12943-021-01391-x.

Authors

Affiliations

¹ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.
² International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China.
³ School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China.
⁴ Jiangsu Aosaikang Pharmaceutical Co.Ltd (ASK pharm), 699 Kejian Road, Nanjing, 211112, China.
⁵ University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing, 100049, China.
⁶ School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai, 201210, China.
⁷ International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China. dingke@jnu.edu.cn.
⁸ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. jding@simm.ac.cn.
⁹ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. hxie@simm.ac.cn.

^# Contributed equally.

PMID: 34404402
PMCID: PMC8369743
DOI: 10.1186/s12943-021-01391-x

No abstract available

PubMed Disclaimer

Erratum for

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Zhang T, Qu R, Chan S, Lai M, Tong L, Feng F, Chen H, Song T, Song P, Bai G, Liu Y, Wang Y, Li Y, Su Y, Shen Y, Sun Y, Chen Y, Geng M, Ding K, Ding J, Xie H. Zhang T, et al. Mol Cancer. 2020 May 13;19(1):90. doi: 10.1186/s12943-020-01202-9. Mol Cancer. 2020. PMID: 32404161 Free PMC article.

References

1. Zhang T, Qu R, Chan S, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19:90. doi: 10.1186/s12943-020-01202-9. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Affiliations

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Authors

Affiliations

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous